Clinical Trials
3 trialsNCT05685602 2026-05-18
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT03777579 2019-08-08
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Suspended